K. Abeywickrama

Nephrotoxicity and hypertension in patients with autoimmune disease treated with cyclosporine.

B. von Graffenried, A. Dieterlé, K. Abeywickrama, 1988, Transplantation proceedings.

Safety and efficacy of everolimus (RAD) as part of a triple immunosuppressive regimen in de novo cardiac transplant recipients: six-month analysis

H. Valantine, D. Mancini, R. Starling, 2002 .

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients

J. Soulillou, A. Schmidt, B. Nashan, 1997, The Lancet.

Efficacy and safety of oral cyclosporin A (CyA; Sandimmun®) for long‐term treatment of chronic severe plaque psoriasis

L. Dubertret, K. Abeywickrama, C. Laburte, 1994, The British journal of dermatology.

Efficacy of low‐dose cyclosporin A in psoriasis: results of dose‐finding studies

G. Feutren, B. Graffenried, P. Timonen, 1990, The British journal of dermatology.

Renal function and blood pressure in psoriatic patients treated with cyclosporin A

G. Feutren, B. Graffenried, K. Abeywickrama, 1990, The British journal of dermatology.

Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study

P. Tak, P. V. van Riel, J. Maldonado-Cocco, 2007, Annals of the rheumatic diseases.

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.

E. Tuzcu, D. Mancini, R. Starling, 2003, The New England journal of medicine.

Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: Results from a double‐blind randomized placebo‐controlled trial

P. Neuhaus, M. Hall, P. Clavien, 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Risk factors for the development of chronic cyclosporine-nephrotoxicity.

M. Mihatsch, G. Thiel, J. Landmann, 1988, Clinical nephrology.

Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis.

D. Renlund, R. Starling, R. Benza, 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years.

A. Yeung, E. Tuzcu, J. Tobis, 2005, Journal of the American College of Cardiology.

Multi-center intravascular ultrasound validation study among heart transplant recipients: outcomes after 5 years

A. Yeung, J. Tobis, H. Valantine, 2004 .

A Lower Incidence of Cytomegalovirus Infection in De Novo Heart Transplant Recipients Randomized to Everolimus

R. Starling, J. Kobashigawa, C. Bara, 2007, Transplantation.